• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Braeburn sets terms for $150m IPO

January 18, 2017 By Sarah Faulkner

Braeburn sets terms for $150m IPOBraeburn Pharmaceuticals said today that it plans to raise $150 million by offering 7,692,308 shares of its common stock. The Princeton, N.J.-based company wrote in regulatory filings that it expects the initial public offering price for its stock to be between $18.00 and $21.00 apiece.

Apple Tree Partners has indicated an interest in buying $50 million of shares of Braeburn’s common stock and has also agreed to purchase $40 million of the company’s common stock in a private placement upon the completion of the public offering.

Braeburn, which plans to list its shares on the Nasdaq market under the symbol “BBRX”, has developed a 6-month buprenorphine implant for the treatment of opioid addiction – the 1st device of its kind to be approved by the FDA. In November last year, the company touted data from a phase III trial of an injectable formulation of buprenorphine for opioid addiction. Braeburn also has additional product candidates in its pipeline that address therapeutic areas of focus such as pain, schizophrenia and spasticity.

The company wrote in a filing to the SEC that it plans to use the $137.2 million in net proceeds from the offering to commercialize its injectable buprenorphine, Probuphine, and advance product candidates through clinical development. Braeburn said it believes the proceeds, along with its cash and cash equivalents, will be sufficient to sustain operations for the next 12 months.

In its regulatory filing, the company reported a revenue of $42,000 for the 9 months ended September 30, 2016. It also cited a 280% increase in expenses, jumping from $20.4 million for the 9 months ended September 30, 2015 to $78 million in the same period this year. Overall, the company saw its net losses grow from $22.6 million in that period last year to $76.8 million this year.

J.P. Morgan, BofA Merrill Lynch, Deutsche Bank and Canaccord Genuity are joint bookrunners on the deal and it is expected to price around January 30, 2017.

Filed Under: Drug-Device Combinations, Featured, Implants, Initial Public Offering (IPO), Wall Street Beat Tagged With: Braeburn Pharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS